EMEA-000876-PIP03-14-M05

Table of contents

Key facts

Invented name
Soliris
Active substance
Eculizumab
Therapeutic area
Neurology
Decision number
P/0514/2020
PIP number
EMEA-000876-PIP03-14-M05
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of neuromyelitis optica spectrum disorders
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating